TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target

[1]  M. Barbacid,et al.  Afatinib restrains K-RAS–driven lung tumorigenesis , 2018, Science Translational Medicine.

[2]  G. Curigliano,et al.  Cetuximab for treating non-small cell lung cancer , 2018, Expert opinion on biological therapy.

[3]  Jiao Wang,et al.  High glucose contributes to the proliferation and migration of non-small-cell lung cancer cells via GAS5-TRIB3 axis , 2018, Bioscience reports.

[4]  H. Ji,et al.  Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib , 2018, Clinical Cancer Research.

[5]  K. Vousden,et al.  The ERBB network facilitates KRAS-driven lung tumorigenesis , 2018, Science Translational Medicine.

[6]  Xia Li,et al.  TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. , 2017, Cancer cell.

[7]  Joshua A. Kritzer,et al.  Diversity-Oriented Stapling Yields Intrinsically Cell-Penetrant Inducers of Autophagy , 2017, Journal of the American Chemical Society.

[8]  T. Betsuyaku,et al.  Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. , 2017, Cancer research.

[9]  A. Nielsen,et al.  MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells , 2017, Oncogenesis.

[10]  H. Cai,et al.  Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-κB pathway. , 2017, Oncology reports.

[11]  H. Cui,et al.  CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR , 2017, Oncogene.

[12]  R. Kurzrock,et al.  Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer , 2017, Molecular Cancer Therapeutics.

[13]  Yi-long Wu,et al.  EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now? , 2016, Trends in pharmacological sciences.

[14]  X. Wang,et al.  GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis. , 2016, Cancer cell.

[15]  M. Ohba,et al.  Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation , 2016, Molecular Cancer Therapeutics.

[16]  D. Mondal,et al.  Tripping on TRIB3 at the junction of health, metabolic dysfunction and cancer. , 2016, Biochimie.

[17]  Xiaojun Tan,et al.  Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. , 2016, Trends in cell biology.

[18]  Haikuo Zhang,et al.  Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors , 2016 .

[19]  Jihe Zhao.  Cancer stem cells and chemoresistance: The smartest survives the raid. , 2016, Pharmacology & therapeutics.

[20]  Wannian Yang,et al.  Stress-induced endocytosis and degradation of epidermal growth factor receptor are two independent processes , 2016, Cancer Cell International.

[21]  K. O'Byrne,et al.  Lung cancer stem cells: The root of resistance. , 2016, Cancer letters.

[22]  Yi Liu,et al.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.

[23]  Neal Rosen,et al.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism , 2016, Science.

[24]  P. Bragado,et al.  The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase , 2015, Clinical Cancer Research.

[25]  Ke Li,et al.  TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations , 2015, Nature Communications.

[26]  H. Varmus,et al.  Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. , 2015, Cancer discovery.

[27]  J. Neal,et al.  Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.

[28]  Yang Zhang,et al.  I-TASSER server: new development for protein structure and function predictions , 2015, Nucleic Acids Res..

[29]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[30]  R. Perona,et al.  Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations. , 2015, International journal of clinical and experimental pathology.

[31]  S. Stylli,et al.  The role of STAT3 signaling in mediating tumor resistance to cancer therapy. , 2014, Current drug targets.

[32]  M. Lampson,et al.  Localized light-induced protein dimerization in living cells using a photocaged dimerizer , 2014, Nature Communications.

[33]  Ji-Eun Kim,et al.  Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. , 2014, The Journal of clinical investigation.

[34]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[35]  J. Xie,et al.  Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll‐like receptor 2‐mediated cell‐penetrating peptide , 2014, International journal of cancer.

[36]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[37]  Y. Hannun,et al.  Sustained Activation of Protein Kinase C Induces Delayed Phosphorylation and Regulates the Fate of Epidermal Growth Factor Receptor , 2013, PloS one.

[38]  E. Cuyás,et al.  IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations , 2013, Scientific Reports.

[39]  L. Vassilev,et al.  Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy , 2013, Proceedings of the National Academy of Sciences.

[40]  S. Singhal,et al.  Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells , 2013, Autophagy.

[41]  J. Bussink,et al.  Hypoxia Regulation of Phosphokinases and the Prognostic Value of pAKT in Breast Cancer , 2013, The International journal of biological markers.

[42]  T. Betsuyaku,et al.  Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC , 2013, Molecular Cancer Research.

[43]  C. McGlade,et al.  The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal sorting of the epidermal growth factor receptor , 2013, Journal of Cell Science.

[44]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[45]  Lin Dong,et al.  Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. , 2013, Biochimica et biophysica acta.

[46]  Yan Zhou,et al.  Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. , 2013, Cancer discovery.

[47]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[48]  Andrea I. McClatchey,et al.  Spatial regulation of receptor tyrosine kinases in development and cancer , 2012, Nature Reviews Cancer.

[49]  G. Sesti,et al.  The mammalian tribbles homolog TRIB3, glucose homeostasis, and cardiovascular diseases. , 2012, Endocrine reviews.

[50]  Ceshi Chen,et al.  WWP1: a versatile ubiquitin E3 ligase in signaling and diseases , 2011, Cellular and Molecular Life Sciences.

[51]  M. McNiven,et al.  Recycling of the Epidermal Growth Factor Receptor Is Mediated by a Novel Form of the Clathrin Adaptor Protein Eps15* , 2011, The Journal of Biological Chemistry.

[52]  D. Beer,et al.  Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. , 2011, Neoplasia.

[53]  V. Calléja,et al.  A direct role for Met endocytosis in tumorigenesis , 2011, Nature Cell Biology.

[54]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[55]  Douglas G Altman,et al.  Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[56]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[57]  Animal Research: Reporting In Vivo Experiments: The ARRIVE guidelines , 2010, Experimental physiology.

[58]  M. Mann,et al.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. , 2009, Molecular cell.

[59]  A. Seth,et al.  The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11 , 2008, Oncogene.

[60]  M. Hung,et al.  Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.

[61]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[62]  T. Hunter.  The age of crosstalk: phosphorylation, ubiquitination, and beyond. , 2007, Molecular cell.

[63]  C. Carlin,et al.  A Structural Model for the Membrane-bound Form of the Juxtamembrane Domain of the Epidermal Growth Factor Receptor* , 2005, Journal of Biological Chemistry.

[64]  H. Hayashi,et al.  TRB3, a novel ER stress‐inducible gene, is induced via ATF4–CHOP pathway and is involved in cell death , 2005, The EMBO journal.

[65]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[66]  Y. Yarden,et al.  Threonine Phosphorylation Diverts Internalized Epidermal Growth Factor Receptors from a Degradative Pathway to the Recycling Endosome* , 2000, The Journal of Biological Chemistry.